Posts

Biogen acquires RayThera in up to $1B deal to bolster preclinical immunology pipeline

on
Biogen has agreed to acquire RayThera Inc. in a deal valued up to $1.0 billion, composed of an upfront cash payment and contingent milestone payments tied to future clinical and regulatory achievements. The acquisition will bring three preclinical anti-inflammatory programs into Biogen’s immunology pipeline, with RayThera’s lead candidate expected to enter Phase 1 clinical development in early Q3 2026. The transaction is subject to customary closing conditions and regulatory approvals, with completion expected in the third quarter of 2026; Biogen will assume full responsibility for development, manufacturing, and global commercialization of the acquired assets. Sources: Biogen to acquire RayThera for $1 billion - Yahoo Finance Biogen pays up to $1B to add RayThera immunology assets - LinkedIn Biogen (BIIB) to Acquire RayThera Inc. for Up to $1 Billion - GuruFocus Biogen Expands Immunology Pipeline with Agreement to Biogen Acquires RayThera to Expand Immunology Pipeline ...

FDA Accepts sBLA for Roche's Lunsumio VELO and Polivy Combination in Relapsed or Refractory Large B-Cell Lymphoma

on

UPDATED: Kardigan buttons up $400M upsized IPO to power heart drugs toward phase 3

on

Pfizer hunts for new CFO as Denton prepares to leave for consumer goods sector

on

F2G and Shionogi Report Positive Phase 3 Results for Oral Antifungal Olorofim in Invasive Aspergillosis

on

Converting nonresponder insights into smarter drug development strategies in immunology

on

In another reversal, FDA gives uniQure accelerated approval path for Huntington's gene therapy

on

Moderna adds commercial chief, expands Stephen Hoge's role

on

Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement

on

Moderna Eyes German Vaccine Facilities as Senate Democrats Push Broad Drug Pricing Reforms

on

After FDA sign-off, Colorado's drug import plan faces tough road ahead

on

Novo Nordisk hit by multi‑million‑dollar ransom demands after major data breach claimed by hacking groups

on

UniQure stock surges after FDA U-turn clears path to gene therapy filing

on